Advertisement
A or ALC or SYK
Which Stock Would AI Choose? Agilent Technologies (A) vs. Alcon (ALC) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- A has shown the strongest recent momentum, supported by a recovery in China, accelerating pharmaceutical demand, and meaningful margin expansion.
- ALC delivered solid sales growth and raised its full-year profitability outlook, though a premium valuation and competitive pressure in implantables remain watch items.
- SYK is recovering from a cybersecurity disruption, but lingering remediation costs and a recent sharp selloff have weighed on sentiment.
- The three companies span distinct health-related markets: analytical laboratory instruments, eye care, and medical devices, limiting direct business overlap.
- Relative positioning favors A on trend consistency, while SYK carries elevated execution risk and ALC trades at a higher earnings multiple.
Introduction
Agilent Technologies, Alcon, and Stryker are three large-capitalization companies frequently screened together by traders and investors seeking exposure to durable, innovation-driven healthcare-adjacent growth. Although all three operate in technically demanding markets, they serve different customers: Agilent supplies analytical and diagnostic laboratory instruments, Alcon focuses on eye care products and surgical equipment, and Stryker manufactures medical devices across orthopedics and surgical technology. This stock comparison examines their recent relative performance, market positioning, and risk profiles to help readers assess which profile aligns with their own objectives in the current environment.
A Overview and Recent Performance
A, Agilent Technologies, is a global leader in analytical instruments, software, services, and consumables for the life sciences, diagnostics, and applied chemical markets. Recent market activity has favored the stock, which has posted a 90-day share-price gain of roughly 30% and a one-year total return above 40%. Sentiment has been lifted by a rebound in China, where revenue grew about 9% in the most recent quarter, and by double-digit growth in pharmaceutical and biotech demand. The company's specialty contract development and manufacturing organization (CDMO, a partner that develops and makes therapies for other firms) business grew nearly 30%, while a strong instrument replacement cycle and healthy orders have supported a book-to-bill ratio above one for ten consecutive quarters. Operating margin expansion and full-year earnings-per-share (EPS) guidance increases have reinforced the positive narrative, though a premium price-to-earnings multiple means expectations are already elevated.
ALC Overview and Recent Performance
ALC, Alcon, is a Swiss-American eye care company operating two segments: Surgical (including implantable lenses, consumables, and equipment) and Vision Care (contact lenses and ocular health). In recent weeks, the stock responded positively after the company reported second-quarter net sales of about $2.78 billion, up 8% year over year, and raised its 2026 margin and EPS growth guidance, partly aided by anticipated U.S. tariff refunds. Growth was led by new equipment launches such as the Unity platform and by dry-eye products including Systane. However, implantables have faced competitive pressure and softness in the cataract procedure market, and the company took a large non-cash charge after discontinuing certain intraocular lens (IOL, an implantable lens used in cataract surgery) programs. Despite healthy top-line momentum, Alcon trades at a notably high earnings multiple relative to peers, which can increase sensitivity to any growth disappointment.
SYK Overview and Recent Performance
SYK, Stryker, is a leading medical technology company spanning MedSurg and Neurotechnology, and Orthopaedics, including the Mako robotic-assisted surgery platform. The company reported a strong second quarter, with revenue up 9.4% to about $6.59 billion and adjusted EPS rising roughly 18%, as production recovered from a first-quarter cybersecurity disruption. Despite the earnings beat, the shares fell in after-hours trading after management narrowed full-year guidance, and more recently the stock has endured a prolonged losing streak that pushed it toward a 52-week low, erasing tens of billions of dollars in market value. Ongoing cybersecurity remediation costs, a peripheral vascular supply disruption, and acquisition integration demands have kept execution risk elevated. Valuation has compressed below the stock's own five-year norm, but investors remain focused on whether the recovery can be sustained through the second half of the year.
Trending AI Robots
For traders seeking a systematic way to navigate divergent setups like these, Tickeron's Trending AI Robots page curates a focused selection of the platform's AI trading bots. Tickeron hosts hundreds of AI-powered trading bots that collectively monitor thousands of different tickers, but only those best suited to current market conditions earn a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, performance history, and basket of tickers, giving users a range of approaches to explore. Browsing the curated list can help traders quickly identify the strategies and instruments currently showing the strongest signals. Visit the Trending AI Robots page to review the latest featured bots and their live statistics.
Head-to-Head Comparison
The clearest contrast among these three names is in their market momentum and risk profiles. A combines the strongest recent price trend with visible growth catalysts, including China recovery, pharmaceutical reshoring, and a multiyear instrument replacement cycle; its main trade-off is a valuation that already reflects much of that optimism. ALC offers steady, product-led growth in a concentrated eye care franchise and improving margins, but its elevated earnings multiple and competitive pressure in implantables temper the upside case. SYK presents the most attractive valuation relative to its own history and a deep product pipeline, yet it carries the heaviest near-term execution risk from cyber remediation, supply constraints, and integration work. In sector terms, A leans toward cyclical lab-equipment demand tied to biotech and semiconductor spending, while ALC and SYK are more anchored to recurring procedure volumes and demographic-driven healthcare demand.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely currently favor A, Agilent Technologies. The stock combines the most consistent recent uptrend, broadening growth drivers, and improving operating margins without the acute operational overhangs weighing on SYK. While ALC is fundamentally sound, its premium valuation and slower momentum make it a less compelling trend candidate at present. This assessment reflects probabilistic, signal-based positioning rather than a definitive outcome, and relative rankings could shift as new earnings data and market conditions emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A | ALC | SYK | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 89 | 53 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 18 Undervalued | 7 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 88 | |
SMR RATING 1..100 | 46 | 88 | 52 | |
PRICE GROWTH RATING 1..100 | 26 | 73 | 63 | |
P/E GROWTH RATING 1..100 | 28 | 13 | 86 | |
SEASONALITY SCORE 1..100 | 35 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYK's Valuation (7) in the Medical Specialties industry is in the same range as A (11) in the Biotechnology industry, and is in the same range as ALC (18) in the Hospital Or Nursing Management industry. This means that SYK's stock grew similarly to A’s and similarly to ALC’s over the last 12 months.
SYK's Profit vs Risk Rating (88) in the Medical Specialties industry is in the same range as A (100) in the Biotechnology industry, and is in the same range as ALC (100) in the Hospital Or Nursing Management industry. This means that SYK's stock grew similarly to A’s and similarly to ALC’s over the last 12 months.
A's SMR Rating (46) in the Biotechnology industry is in the same range as SYK (52) in the Medical Specialties industry, and is somewhat better than the same rating for ALC (88) in the Hospital Or Nursing Management industry. This means that A's stock grew similarly to SYK’s and somewhat faster than ALC’s over the last 12 months.
A's Price Growth Rating (26) in the Biotechnology industry is somewhat better than the same rating for SYK (63) in the Medical Specialties industry, and is somewhat better than the same rating for ALC (73) in the Hospital Or Nursing Management industry. This means that A's stock grew somewhat faster than SYK’s and somewhat faster than ALC’s over the last 12 months.
ALC's P/E Growth Rating (13) in the Hospital Or Nursing Management industry is in the same range as A (28) in the Biotechnology industry, and is significantly better than the same rating for SYK (86) in the Medical Specialties industry. This means that ALC's stock grew similarly to A’s and significantly faster than SYK’s over the last 12 months.
| A | ALC | SYK | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 64% | 1 day ago 50% | 1 day ago 83% |
| Stochastic ODDS (%) | 1 day ago 68% | 1 day ago 60% | 1 day ago 67% |
| Momentum ODDS (%) | 1 day ago 63% | N/A | 1 day ago 63% |
| MACD ODDS (%) | 1 day ago 60% | N/A | 1 day ago 74% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 50% | 1 day ago 55% |
| TrendMonth ODDS (%) | 1 day ago 61% | 1 day ago 51% | 1 day ago 53% |
| Advances ODDS (%) | 1 day ago 62% | 8 days ago 57% | 1 day ago 57% |
| Declines ODDS (%) | 6 days ago 63% | 5 days ago 55% | 6 days ago 51% |
| BollingerBands ODDS (%) | 1 day ago 68% | 1 day ago 59% | 1 day ago 68% |
| Aroon ODDS (%) | 1 day ago 65% | 1 day ago 54% | 1 day ago 45% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 3 FA rating(s) are green while ALC’s FA Score has 2 green FA rating(s), and SYK’s FA Score reflects 1 green FA rating(s).
- A’s FA Score: 3 green, 2 red.
- ALC’s FA Score: 2 green, 3 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 4 TA indicator(s) are bullish while ALC’s TA Score has 4 bullish TA indicator(s), and SYK’s TA Score reflects 5 bullish TA indicator(s).
- A’s TA Score: 4 bullish, 4 bearish.
- ALC’s TA Score: 4 bullish, 4 bearish.
- SYK’s TA Score: 5 bullish, 5 bearish.
Price Growth
A (@Medical Specialties) experienced а -2.24% price change this week, while ALC (@Pharmaceuticals: Other) price change was -1.43% , and SYK (@Medical/Nursing Services) price fluctuated +3.93% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.18%. For the same industry, the average monthly price growth was +3.31%, and the average quarterly price growth was +49.58%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.80%. For the same industry, the average monthly price growth was -3.39%, and the average quarterly price growth was +15.53%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.22%. For the same industry, the average monthly price growth was -4.30%, and the average quarterly price growth was -2.12%.
Reported Earning Dates
A is expected to report earnings on Nov 30, 2026.
ALC is expected to report earnings on Nov 10, 2026.
SYK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Medical Specialties (-1.18% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (-0.80% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-0.22% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
ALC and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALC has been loosely correlated with SYK. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALC jumps, then SYK could also see price increases.
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.